Migraine prophylaxis with divalproex

Archives of Neurology

Volumn 52, Issue 3, 1995, Pages 281-286

  Mathew, Ninan T ^a   Saper, Joel R ^b   Silberstein, Stephen D ^b   Rankin, Lynn ^c   Markley, Herbert G ^d   Solomon, Seymour ^e   Rapoport, Alan M ^b   Silber, Christopher J ^b   Deaton, Roger L ^b  

^a Houston   (United States)

^b Michigan Head Pain and Neurological Institute Ann Arbor ^*  (United Kingdom)

^c UNIVERSITY OF ARIZONA   (United States)

^d Herefordshire and Worcestershire Lifelong Learning Network   (United Kingdom)

^e MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VALPROATE SEMISODIUM;

ADULT; ALOPECIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREMOR;

ADOLESCENT; ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PLACEBOS; VALPROIC ACID;

EID: 0028934233     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.1995.00540270077022     Document Type: Article

References (19)

1. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. JAMA. 1992;267:64-69.
2. Welch KMA, Chabi E, Bartosh K, Achar VS, Meyer JS. Cerebrospinal fluid gammaaminobutyric acid levels in migraine. BMJ. 1975;3:516-517.
3. Ferrari MD, Odink J, Bos KD, Malessy MJA, Bruyn GW. Neuroexcitatory plasma amino acids are elevated in migraine. Neurology. 1990;40:1582-1586.
4. Sorensen KV. Valproate: a new drug in migraine prophylaxis. Acta Neurol Scand. 1988;78:346-348.
5. Hering R, Kuritzky A. Sodium valproate in the treatment of cluster headache: an open clinical trial. Cephalalgia. 1989;9:195-198.
6. Mathew NT, Ali S. Valproate in the treatment of persistent chronic daily headache: an open label study. Headache. 1991;31:71-74.
7. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia. 1992;12:81-84.
8. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-96.
9. Van Elteren PH. On the combination of independent two sample tests of Wilcoxon. Bull Inst Int Stat. 1960;37:351-361.
10. Lehmann EL. Nonparametrics: Statistical Methods Based on Ranks. San Francisco, Calif: Holden-Day; 1975.
11. US Department of Health and Human Services. COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms. 3rd ed. Rockville, Md: US Dept of Health and Human Services, Food and Drug Administration, Center for Drugs and Biologics, Division of Drug and Biological Product Experience; 1989.
12. Couch JR Jr. Placebo effect and clinical trials in migraine therapy. Neuroepidemiology. 1987;6:178-185.
13. Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol. 1979;36:695-699.
14. Cotariu D, Zaidman JL, Evans S. Neurophysiological and biochemical changes evoked by valproic acid in the central nervous system. Prog Neurobiol. 1990; 34:343-354.
15. Vion-Dury J, Cupo A, Jarry T. Analgesic properties of valproic acid might be related to activation of proenkephalin system in rat brain. Brain Res. 1987; 408:243-246.
16. Welch KM, D'Andrea G, Tepley N, Barkley G, Ramadan NM. The concept of migraine as a state of central neuronal hyperexcitability. Neurol Clin. 1990;8: 817-828.
17. Simon D, Penry JK. Sodium di-n-propylacetate (DPA) in the treatment of epilepsy: a review. Epilepsia. 1975;16:549-573.
18. Dreifuss FE, Langer DH, Moline KA, Maxwell JE. Valproic acid hepatic fatalities, II: US experience since 1984. Neurology. 1989;39:201-207.
19. Dreifuss FE, Langer DH. Side effects of valproate. Am J Med. 1988;84(suppl 1A):34-41.